PD-1/PD-L1抑制剂在食管鳞状细胞癌治疗中的进展

Advances of PD-1/PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma

在亚洲食管癌确诊病例中,食管鳞状细胞癌(ESCC)占90%以上,且恶性程度高。目前针对ESCC免疫治疗的研究越来越多,尤其是关于程序性死亡蛋白-1(PD-1)和程序性死亡蛋白-配体1(PD-L1)的研究。在ESCC中研究最多的PD-1/PD-L1抑制剂主要有纳武单抗、帕博利珠单抗、卡瑞利珠单抗、特瑞普利单抗、替雷利珠单抗、阿特珠单抗、SHR-1316和度伐利尤单抗,这些药物的临床试验部分已经初步显示出良好的疗效,部分研究还在进行中。

Esophageal squamous cell carcinoma(ESCC)accounts for more than 90%of the confirmed cases of esophageal cancer in Asia,and the degree of malignancy is high.There is a growing number of research on ESCC immunotherapy,particularly programmed death-1(PD-1)and programmed death-ligand 1(PD-L1).Among them,the most studied PD-1/PD-L1 inhibitors in ESCC are nivolumab,pembrolizumab,camrelizumab,toripalimab,tislelizumab,atozolizumab,SHR-1316 and durvalumab.Some of the clinical trials of these drugs are still in progress,and some have initially shown good results.